Find a Provider
About
Clinical Research
- Scientific Evidence
- Clinical Trials
Blog
News
Contact Us

Newsroom

For press inquiries, please contact Amy Cook
email: amy@magnusmed.com
phone: 925.222.5094

Featured On

CBS Sunday Morning with Jane Pauley

Latest News

Magnus Medical Announces Uninterrupted 2026 Payment Stability for SAINT Neuromodulation in CMS OPPS Final Rule

Researchers investigate new revolutionary 5-day therapy for treatment-resistant depression

Join Us

We are looking for individuals who are personally and boldly committed to improving treatment for mental health.

View open positions HERE

Contact Us

	1350 Old Bayshore Highway Suite 600 Burlingame CA 94010 USA
	1-888-537-1530
	support@magnusmed.com

Rx Only
The SAINT® Neuromodulation System is indicated for the treatment of Major Depressive Disorder (MDD) in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. The SAINT Neuromodulation System is contraindicated for: patients with non-removable conductive, ferromagnetic, or other magnetic-sensitive metal anywhere in the head or within 30cm of the stimulation coil; patients who have an active or inactive implanted device; or patients with increased intracranial pressure or intracardiac lines, intravenous pumps, or dose calculators. Consult product labeling for a complete list of contraindications, warnings, and precautions. Side effects including headache, fatigue, anxiety, and treatment-site discomfort were shown in clinical trials. Risks associated with transcranial magnetic stimulation, including seizure and worsening depression or suicidality, may exist. Results may vary.

Financial Conflict of Interest Policy

Sitemap

© 2025 Magnus Medical. MAGNUS MEDICAL and the MAGNUS MEDICAL Logo are the trademarks of Magnus Medical, Inc.
SAINT, the SAINT Logo and SNT are used under license from Stanford University.